AR124247A1 - Métodos de tratamiento del lupus eritematoso cutáneo y lupus eritematoso sistémico - Google Patents

Métodos de tratamiento del lupus eritematoso cutáneo y lupus eritematoso sistémico

Info

Publication number
AR124247A1
AR124247A1 ARP210103370A ARP210103370A AR124247A1 AR 124247 A1 AR124247 A1 AR 124247A1 AR P210103370 A ARP210103370 A AR P210103370A AR P210103370 A ARP210103370 A AR P210103370A AR 124247 A1 AR124247 A1 AR 124247A1
Authority
AR
Argentina
Prior art keywords
seq
amino acid
acid sequence
lupus erythematosus
sequence indicated
Prior art date
Application number
ARP210103370A
Other languages
English (en)
Inventor
Francois Gaudreault
Himanshu Naik
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of AR124247A1 publication Critical patent/AR124247A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan regímenes de dosificación de anticuerpos contra el antígeno de células dendríticas de la sangre 2 para el uso en el tratamiento del lupus eritematoso cutáneo y lupus eritematoso sistémico. Reivindicación 35: Una jeringa precargada que comprende una preparación estéril de un anticuerpo anti-BDCA2, donde la jeringa precargada se encuentra adaptada para la administración subcutánea del anticuerpo anti-BDCA2 en una dosis fija de 225 mg, y donde el anticuerpo anti-BDCA2 comprende un dominio variable de cadena pesada (VH) de inmunoglobulina y un dominio variable de cadena ligera (VL) de inmunoglobulina, donde el VH y VL, respectivamente, comprenden: (a) las regiones de determinación de la complementariedad (CDR) del VH VH-CDR1, VH-CDR2 y VH-CDR3, donde la VH-CDR1 comprende la secuencia de aminoácidos que se indica en la SEQ ID Nº 1; la VH-CDR2 comprende la secuencia de aminoácidos que se indica en la SEQ ID Nº 2; y la VH-CDR3 comprende la secuencia de aminoácidos que se indica en la SEQ ID Nº 3; y (b) las CDR del VL VL-CDR1, VL-CDR2 y VL-CDR3, donde la VL-CDR1 comprende la secuencia de aminoácidos que se indica en la SEQ ID Nº 4; la VL-CDR2 comprende la secuencia de aminoácidos que se indica en la SEQ ID Nº 5; y la VL-CDR3 comprende la secuencia de aminoácidos que se indica en la SEQ ID Nº 6.
ARP210103370A 2020-12-03 2021-12-03 Métodos de tratamiento del lupus eritematoso cutáneo y lupus eritematoso sistémico AR124247A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063121194P 2020-12-03 2020-12-03

Publications (1)

Publication Number Publication Date
AR124247A1 true AR124247A1 (es) 2023-03-01

Family

ID=79024222

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210103370A AR124247A1 (es) 2020-12-03 2021-12-03 Métodos de tratamiento del lupus eritematoso cutáneo y lupus eritematoso sistémico

Country Status (15)

Country Link
US (1) US20240018246A1 (es)
EP (1) EP4255392A1 (es)
JP (1) JP2024501430A (es)
KR (1) KR20230119664A (es)
CN (1) CN116963716A (es)
AR (1) AR124247A1 (es)
AU (1) AU2021391803A1 (es)
CA (1) CA3203971A1 (es)
CL (1) CL2023001562A1 (es)
CO (1) CO2023008272A2 (es)
IL (1) IL303279A (es)
MX (1) MX2023006474A (es)
PE (1) PE20231678A1 (es)
TW (1) TW202222829A (es)
WO (1) WO2022120144A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1301539B1 (en) * 1999-11-15 2007-01-17 Miltenyi Biotec GmbH Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
AU2013359419B2 (en) 2012-12-10 2018-03-15 Biogen Ma Inc. Anti-blood dendritic cell antigen 2 antibodies and uses thereof
WO2015098813A1 (ja) * 2013-12-24 2015-07-02 アステラス製薬株式会社 新規抗ヒトｂｄｃａ－２抗体
US20190284281A1 (en) * 2016-04-28 2019-09-19 Biogen Ma Inc. Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies

Also Published As

Publication number Publication date
WO2022120144A1 (en) 2022-06-09
MX2023006474A (es) 2023-08-16
CO2023008272A2 (es) 2023-09-29
CL2023001562A1 (es) 2023-12-15
TW202222829A (zh) 2022-06-16
IL303279A (en) 2023-07-01
US20240018246A1 (en) 2024-01-18
JP2024501430A (ja) 2024-01-12
AU2021391803A1 (en) 2023-07-06
EP4255392A1 (en) 2023-10-11
PE20231678A1 (es) 2023-10-19
KR20230119664A (ko) 2023-08-16
CA3203971A1 (en) 2022-06-09
CN116963716A (zh) 2023-10-27

Similar Documents

Publication Publication Date Title
US20230058395A1 (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
Ribeiro et al. Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis
JP6877357B2 (ja) Ｇｄｆ８阻害剤を用いて、強度及び機能を増加させる方法
TWI604851B (zh) Ｉｌ－１７抗體用於製備治療強直性脊椎炎之藥物之用途
NO343797B1 (no) Flytende farmasøytisk formulering inneholdende CD40-antistoff og anvendelse av slike.
JP2022033891A (ja) 関節リウマチを治療するための組成物およびこれを使用する方法
JP2022105160A (ja) 関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和ｇｍ－ｃｓｆ
RU2697383C2 (ru) Применение антагонистов il-17 для торможения прогрессирования структурных повреждений у пациентов с псориатическим артритом
JP7266108B2 (ja) 治療用抗体製剤
ES2721378T3 (es) Anticuerpos anti-TLR4 y métodos de uso de los mismos
JP2019521156A5 (es)
JP2023138982A (ja) インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して腱障害を治療する方法
Berg et al. A review of secukinumab in psoriasis treatment
JP2017527546A (ja) 抗ＴＮＦ−α抗体療法を受けた乾癬患者を治療するための方法
TW202026035A (zh) 用來治療患有類風濕性關節炎之個體的方法及組成物
AR124247A1 (es) Métodos de tratamiento del lupus eritematoso cutáneo y lupus eritematoso sistémico
JP2017532332A (ja) 炎症性疾患の治療に使用するための乳酸トランスポーターの阻害剤
Albu et al. CTX-8371, a novel bispecific targeting both PD-1 and PD-L1, is more potent than combination anti-PD-1 and PD-L1 therapy and provides enhanced protection from tumors in vivo
Tarner et al. SAT0039 In vivo fluorescence-imaging of matrix metalloproteinase activity and response to therapy in an animal model of rheumatoid arthritis
Sharma et al. ODN 2216 Uptake Induced TLR9 Signaling Mediates Phenotypic Changes in CD4+ T Cells
WO2024121380A1 (en) Vaccinal composition and adjuvant
RU2020134794A (ru) Способы лечения хронической спонтанной крапивницы с применением лигелизумаба
TW202041536A (zh) 藉由投與il-4r拮抗劑治療異位性皮膚炎的方法
RU2023102788A (ru) Лечение гнойного гидраденита с использованием антагонистов il-17
Matubu et al. an inhibitor of GPX4 Menu